Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

The ORR was 69% (95% CI, 61-76) in the zanubrutinib arm and 46% (95% CI, 34-58) in the obinutuzumab monotherapy arm. The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa ...

Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 ...

Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...

A single-center real-world study compares the effectiveness and toxicity of chimeric antigen receptor T-cell therapy vs ...

Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

A childhood cancer diagnosis can be unpredictable. What will the treatment be? Will it work? Will my child relapse? Ailani Myers, 9, has relapsed seven times, but her motto remains the same. "We've ...